p53 mutation and tamoxifen resistance in breast cancer.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

p53 mutation and tamoxifen resistance in breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 1995

Elledge R M, Lock-Lim S, Allred D C, Hilsenbeck S G, Cordner L

Abstract excerpt

A substantial portion of patients with estrogen receptor-positive breast cancer fail to respond to estrogen depletion or to the antiestrogen tamoxifen. The molecular changes that lead to tamoxifen resistance and estrogen-independent growth are unknown. To test the hypothesis that a p53 mutation c...

Topics

Antineoplastic Agents, Hormonal
Breast Neoplasms
Cell Division
Drug Resistance, Neoplasm
Female
Genes, p53
Genetic Vectors
Humans
Mutation
Tamoxifen
Transfection
Tumor Cells, Cultured
Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 9815913

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9815913-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics